France prostate cancer market is forecast to grow at a CAGR of 11.5% during the forecast period. The country is among the most susceptible to the prostate cancer in Europe. As per the World Health Organization, around 25% of the overall cancer cases are of prostate cancer, which is around 65,000 in 2018. The 5-year prevalence in the country due to prostate cancer is around 228,000 in 2018. In the country, obesity is one of the major factors of prostate cancer. The country has a high consumption of alcohol, smoking, a high level of animal fat consumption, serum total cholesterol and high-density lipoprotein cholesterol concentrations. Due to this, individuals are more prone to becoming obese increasing their chances of being affected with prostate cancer.
Government initiatives for prostate cancer management are one of the factors augmenting the demand for prostate cancer diagnostic and therapeutic. France government has been actively supporting the healthcare system with most of the chronic diseases, 100% covered by French statuary health insurance. The healthcare system in France is one of the universal healthcare majorly financed by government national health insurance. The state covers the healthcare costs of residents not eligible for Statuary Health Insurance (SHI). The state also covers illegal immigrants who have applied for residency, as well as residents from the EU. Non-EU visitors are covered for emergency services only.
France prostate cancer diagnostic and therapeutics market has segmented based on diagnostic techniques and therapeutics. By diagnosis technique, prostate biopsy is expected to hold a major market share during the forecast period. By therapeutics, chemotherapy is expected to have a major market share in the country. The companies which are contributing significantly in the market include Abbott Laboratories, AbbVie Products, LLC, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Siemens Healthcare AG, and others. The market players are considerably contributing to the market growth by the adoption of various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Research Methodology
The market study is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. In the report, the analysis of the country is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to brings authenticity to the reports.
Secondary Sources Include
The report is intended for drug manufacturing companies, medical device manufacturing companies, contract manufacturers, government organizations, and venture capitalists for the comprehensive market analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. France Prostate Cancer Market by Diagnostic Techniques
5.1.1. Prostate-Specific Antigen Test (PSA)
5.1.2. Digital Rectal Examination
5.1.3. Prostate Biopsy
5.1.4. Imaging Techniques
5.2. France Prostate Cancer Market by Therapeutics
5.2.1. Hormonal Therapy
5.2.2. Chemotherapy
5.2.3. Immunotherapy
5.2.4. Radiation Therapy
5.2.5. Targeted Therapy
5.2.6. Surgery
6. Company Profiles
6.1. Abbott Laboratories
6.2. AbbVie Products, LLC
6.3. Amgen Inc.
6.4. AstraZeneca PLC
6.5. Bayer AG
6.6. Bristol-Myers Squibb Co.
6.7. Ferring Pharmaceuticals Inc.
6.8. GlaxoSmithKline PLC
6.9. Johnson & Johnson
6.10. Pfizer Inc.
6.11. Siemens Healthcare AG
6.12. Ipsen Group
1. FRANCE PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2018-2025 ($ MILLION)
2. FRANCE PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)
1. FRANCE PROSTATE CANCER MARKET SHARE BY DIAGNOSTIC TECHNIQUE, 2018 VS 2025 (%)
2. FRANCE PROSTATE CANCER MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)